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Kratak sadr`aj
Uvod: Cilj studije bio je da se ispita uticaj protokola stimu-
lacije sa GnRH agonistima i antagonistima na parametre
oksidativnog stresa u serumu, kao i uticaj poreme}aja para-
metara oksidativnog stresa na ishod IVF ciklusa. 
Metode: Istra`ivanje je obuhvatilo 82 pacijentkinje koje su
bile uklju~ene u postupak vantelesnog oplo|enja (VTO).
Odre|ivali smo slede}e markere oksidativnog stresa u seru-
mu: aktivnost SOD, koncentraciju MDA i SH grupe. Uzorci
su bili uzimani izme|u drugog i ~etvrtog dana ciklusa i na
dan administracije hCG u toku stimulacije. 
Rezultati: Pacijenti su bili podeljeni u dve grupe zavisno od
primenjenog protokola stimulacije sa GnRH agonistima i
GnRH antagonistima. Prose~an broj jajnih }elija, broj zrelih
jajnih }elija i broj fertilisanih jajnih }elija bili su ve}i u grupi
sa GnRH agonistima. Nije bilo zna~ajne razlike u stopama
biohemijskih trudno}a, poba~aja i stopama `ivoro|enosti
izme|u dve grupe. Prose~ne vrednosti aktivnosti SOD u
serumu bile su zna~ajno ni`e, dok su prose~ne vrednosti
koncentracija MDA i SH grupa bile zna~ajno vi{e posle
zavr{ene ovarijalne stimulacije. Stope poro|aja bile su ve}e
kod pacijentkinja bez oksidativnog stresa, dok su stope
poba~aja bile vi{e kod pacijentkinja sa prisutnim oksidativ-
nim stresom posle stimulacije. 
Zaklju~ak: Na{a studija je potvrdila da postoji razlika u kon-
centracijama markera oksidativnog stresa u serumu pre i
posle stimulacije, nezavisno od protokola stimulacije. Ishod
IVF postupka je bolji kod pacijentkinja kod kojih oksida tivni
stres nije aktiviran posle ovarijalne stimulacije. Protokol sti-
mulacije nije uticao na promenu parametara oksidativnog
stresa u serumu, niti na ishod IVF postupka.
Klju~ne re~i: protokoli stimulacije, oksidativni stres,
ishod IVF 
Summary 
Background: Our aim was to study the effect of GnRH ago-
nist and antagonist protocols of ovarian stimulation on
oxidative stress parameters in serum and the influence of
oxidative stress parameters change on the outcome of IVF
cycles. 
Methods: This prospective study included 82 patients who
un der went IVF procedures. We determined SOD, MDA
and SH groups in serum. Serum samples were obtained
between the second and fourth day of the cycle and on the
day of HCG administration during ovarian stimulation. 
Results: Patients were divided into two groups depending
on the protocol of stimulation. The mean total and mature
oocytes number and number of fertilized oocytes were
higher in GnRH agonist group. There was no significant
difference in biochemical pregnancy, miscarriage and live
–birth rate in both groups. Mean serum SOD was signifi-
cantly lower, while mean serum MDA and SH groups were
significantly higher after ovarian stimulation. Delivery rate
was higher in patients without OS while miscarriage rate
was higher in patients with OS. 
Conclusions: Our study confirmed that there is a difference
in the concentration of oxidative stress parameters before
and after ovarian stimulation. IVF outcome is better in
patients without OS after ovarian stimulation. However, the
protocol of ovarian stimulation is neither associated with a
change in oxidative stress parameters nor with the outcome
of ART procedures. 
Keywords: stimulation protocols, oxidative stress, IVF
outcome
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Introduction
The outcome of ART procedures is affected by
several factors including the protocol of ovarian stim-
ulation and oxidative stress. Controlled ovarian stimu-
lation is part of assisted reproductive procedures and
several protocols are designed with the combination
of GnRH agonists and antagonists and gonado -
tropins. 
Long-acting GnRH agonists were introduced in
the late 1980s to ovarian stimulation in ART to down-
regulate endogenous pituitary gonadotropin secretion
and prevent premature LH surge during exogenous
gonadotropin stimulation. In the typical »long proto-
col«, GnRH agonist application begins in the mid-
luteal phase with an acute reaction and release of
stored pituitary gonadotropins in the response known
as »Flare effect«, and then suppresses endogenous
gonadotropin secretion during the next 10 days and
longer while occupying the receptor. When agonist
treatment begins in the luteal phase, gonadotropin
stimulation yields more follicles and oocytes, while the
ovarian stimulation itself is longer (1). Contrary to the
long-acting agonists, the GnRH antagonists block the
GnRH receptor in a competitive, dose-dependent
manner, and with no flare effect. The effect is almost
immediate and the administration of GnRH antagonist
is needed on a daily basis. The only purpose of antag-
onist use is to prevent premature LH surge. Anta -
gonists suppress endogenous gonado tropin secretion
more completely than agonists. The duration of stim-
ulation is shorter, and the total dose of exogenous
gonadotropins is decreased (2).
The choice of protocol is usually based on the
clinical characteristics of the patient, which include
the age, BMI, cause of infertility, the outcome of pre-
vious IVF attempts, as well as the parameters of ovar-
ian reserve – basal FSH, estradiol, AMH and antral
follicle count (AFC).
Ovarian stimulation may have a direct impact
on oxidative stress markers and it is associated with
the production of Reactive Oxygen Species (ROS)
and perturbation of oxidant-antioxidant balance (3).
Although oxidative stress has been suggested as an
important factor that negatively affects the outcome
of in vitro fertilization, there is only a small number of
studies that investigated the effects of oxidative stress
parameters disbalance on the outcome of ART proce-
dures in women (4–6). 
Physiological levels of ROS in the female repro-
ductive tract play a role in folliculogenesis, ovulation
(7, 8), sperm-oocyte interaction, fertilization (9),
implan tation and early embryo development. How -
ever, the increased production of ROS can adversely
affect the microenvironment in the reproductive tract
and the normal physiological process (10), which
eventually affects the course and outcome of preg-
nancy (11). 
The aim of this study was to investigate the influ-
ence of long GnRH agonist and short GnRH antago-
nist protocols of ovarian stimulation on the oxidative
stress parameters in serum as well as the influence of
change in oxidative stress parameters on IVF out -
come: number of received oocytes, number of mature




This prospective clinical study was conducted at
the Clinic of Gynecology and Obstetrics, Clinical
Center of Serbia. We recruited 82 patients admitted
for fertility treatment. All investigated patients agreed
to participate in the study and signed an informed
consent for all the undertaken procedures. The study
was approved by the Ethics Committee of the Faculty
of Medicine, University of Belgrade. Including criteria
were: age 18–40 years, BMI from 18 to 30 kg/m2,
regular menstrual cycles from 25–32 days and with-
out any medical disease or endometriosis stage III
and IV. For all patients, age, body mass index (BMI),
years of treating infertility, smoking status (smoker/
non smoker) and the cause of infertility were deter -
mined. Infertility cause was categorized as male, tubal,
ovarian, unknown or combined. The protocols of sti -
mu lation were determined individually. Patients were
submitted to short GnRH antagonist protocols (n=58)
and long GnRH agonist protocols (n=24), depending
on age, ovarian reserve and previous IVF cycle. 
Controlled ovarian stimulation protocols 
Patients on a long agonist protocol received
Triptoreline (Diphereline, Ipsen Pharma Biotech,
France) at a dose of 0.1 mg daily starting in the mid-
luteal phase of the previous cycle. After suppression
of the pituitary, recombinant FSH – follitropin a (Go -
nal-F, Serono, Switzerland) was commenced at a dose
of 150–300 IU/day. Patients on a short GnRH anta -
gonist protocol received the same gonadotropin sti -
mu lation starting on cycle day two or three, after the
proper ultrasound findings and basal hormone levels.
GnRH Antagonists – Cetrorelix (Cetrotide) at a dose
of up to 0.25 mg per day were added when the lead-
ing follicle reached a diameter of 14 mm and were
administered by the day of HCG. 
When there was a consistent rise in the concen-
tration of estradiol followed by the presence of two or
more follicles > 18 mm, human chorionic gonado -
tropin (Pregnyl, Organon, the Netherlands) was
administered at a dose of 5000 IU, 34–36 hours
before oocyte retrieval. Methods of insemination were
IVF, ICSI, or a combined method. In assessing the
quality of embryos, the Istanbul consensus clinical
em bryologists criteria were used as the reference
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frame (12). Embryo transfer was performed transcer-
vically on day 2 or 3 after the oocyte retrieval, con-
trolled by transabdominal ultrasonography. Patients
received Utrogestan (micronized progesterone) at a
dose of 200 mg, three times daily, for luteal phase
support, and continued until the 12th week of gesta-
tion. Pregnancy was diagnosed by positive serum b-hCG
and then confirmed as clinical pregnancy by ultra-
sound findings: gestational sac with a vital em bryo
and the 6-week gestation. Finally, we registered
whether patients had a term delivery or a miscarriage.
Sample collection and determination of oxidative
stress parameters
Serum levels of estradiol (E2 – pg/mL), proges-
terone (PROG – ng/mL), follicle-stimulating hormone
(FSH – mIU/mL), luteinizing hormone (LH –
mIU/mL) and anti-Mullerian hormone (AMH – ng/L)
were measured between the 2nd and 4th cycle day
prior to stimulation commencement (basal levels).
Blood samples were taken by Vacutainer tubes (BD
Vacutainer Systems) and centrifuged according to
the manufacturer’s instructions for the preparation
of serum samples. AMH value (Gen II ELISA ref. No.
A79765; Beckman Coulter) in serum was measured
by ELISA (enzyme-linked immunosorbent assay, 1
ng/mL). FSH, LH, estradiol and progesterone were
analyzed by chemiluminescent immunoassay (Access
2 immunoassay system, Beckman Coulter) (13, 14).
Serum samples for oxidative stress parameters
were obtained from each patient when the basal hor-
monal status was determined. The second time point
when serum samples were obtained was on the day
of HCG administration. The following parameters of
oxidative stress were determined in serum: activity of
SOD and concentrations of MDA and SH groups.
After separation, the serum/plasma was frozen
and stored at a temperature of –70 °C. After incom-
plete defrosting, by a quick procedure on ice (0–4
°C), preparation of the serum for the analysis was car-
ried out by homogenization and centrifugation. After
preparing a serum sample, OS parameters, malon -
dialdehyde (MDA), the activity of total superoxide
dismutase (SOD) and the concentration of total
sulfhydryl (SH) groups were determined. Proteins
were determined by the Bradford method, based on
colors for the binding of a protein molecule, wherein
there is a shift of the absorption maximum, as com-
pared to the color of the absorption maximum of the
free form (15). Determination of MDA in serum was
based on the reaction of MDA with thiobarbituratic
acid (TBA) in an acidic medium for 15 minutes at 95
°C in a water bath. The intensity of light yellow to vio-
let was measured at wavelengths of 523 nm and 600
nm, in order to remove interference. The activity of
superoxide dismutase (SOD, EC 1.15.1.1.) in the
serum was determined by the method of Misra and
Fridovich, at a wavelength of 480 nm, by a kinetic
method in an alkaline environment. The total concen-
tration of SH groups was determined by Ellman’s
method (16). The absorbance of the yellow color was
measured at 412 nm, and was based on the reaction
with 2,2-dinitro-5,5-dithio-benzoic acid (DTNB) with
an aliphatic thiol compound in an alkaline medium
(pH = 9.0), thereby forming a p-nitrophenyl anion. 
Statistical analysis
For statistical analysis of the obtained data, the
Statistical Package for the Social Sciences (SPSS) 22
was used and differences were considered statistically
significant at a probability level less than 0.05 for all
tests. Results were presented as arithmetic mean ±
standard deviation for variables with a normal distri -
bution and as median and interquartile range for
variables whose distribution was not normal. Cate -
gorical variables are presented as relative or absolute
frequency. Testing of distribution was carried out by
Kolmogorov-Smirnov analysis. Comparison of the
mean values  of independent groups of data was
performed by Student t-test and ANOVA analysis with
Tukey’s post hoc test for differences between sub -
groups. For parameters without normal distribution,
test of significance between groups was performed
using the Mann Whitney test or Kruskal-Wallis test
with post hoc Mann Whitney test. Comparison of two
dependent populations was performed by Wilcoxon
signed-rank test for data without normal distribution.
Analysis of categorical values  was performed using
the Chi-square test. 
Results
The general characteristics and clinical data of
the study population are given in Table I. There is a
difference in age between GnRH antagonist
(GnRHant) and GnRH agonist (GnRHa) protocols
(35.5 vs. 32.2; p=0.002). In the group with
GnRHant protocol, AMH values were significantly
lower compared to the group with GnRHa (0.95 vs.
2.3; p=0.014), while FSH values were higher (7.87
vs. 6.65; p=0.041). However, basal values of LH,
estradiol and progesterone were similar in both
groups. Patients with a GnRH agonist protocol had a
significantly higher number of oocytes (12 vs. 4;
p<0.001) as well as of mature oocytes (9 vs. 4;
p<0.001). Similarly, the number of fertilized oocytes
was higher in the GnRHa group (5 vs. 2; p=0.009).
However, fertilization rate was similar in both groups
(p=0.398). The most frequent infertility cause was
male in the GnRHa protocol (40%) while in the
GnRHant protocol it was ovarian (32%). There was
no significant difference in the cause of infertility
among patients with different protcols of ovarian
stimulation (p=0.079; c2 test).
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Table I General characteristics, basal hormonal status, number and quality of oocytes, number of fertilized oocytes and fertiliza-
tion rate of the study population.
Table II Comparison of serum concentrations of OS parameters before and after ovarian stimulation in the group with GnRH an -
tagonist and the agonist group.
Arithmetic mean values ± SD for normally distributed variables or median (inter-quartile range) for variables that do not have a
normal distribution are shown. According to a ANOVA test; according to b Kruskal-Wallis test. * Significant difference compared
to the long protocol.
The median (25th and 75th percentile) values are shown. The comparison was made using Wilcoxon signed-rank test (compari-
son of two dependent populations).
The median (25th and 75th percentile) values are shown. Comparison of values after stimulation was performed by Kruskal Wallis
test.
Table III Comparison of serum concentrations of OS parameters after ovarian stimulation between GnRH antagonist group and
GnRH agonist group.
Parameters GnRH antagonists GnRH agonists P
Age 35.5±4.0* 32.2±2.9 0.002a
BMI, kg/m2 22.13±2.52 22.21±3.52 0.592a
Smoker, % 28.8 20.0 0.587
Infertility, years 5 (4–6) 4 (3–5) 0.250b
FSH, mIU/mL 7.87±2.69 6.65±1.84 0.041a
AMH, ng/mL 0.95 (0.42–2.79)* 2.30 (1.28–4.08) 0.014b
E2, pg/mL 44.88±20.95 42.9±18.13 0.755a
LH, mIU/mL 5.18 ±1.95 4.23±0.95 0.252a
P4, ng/mL 1.26±0.46 1.1±0.36 0.725a
GT dose, IU 2209.25±577.61 2354.78±641.68 0.625a
Oocyte No 4 (1–10)* 12(6–14) <0.001b
Mature oocyte No 4 (2–8) * 9 (5–12) 0.001b
No of fertilized oocytes 2 (1–5)* 5 (3–8) 0.009b
Fertilization rate, % 50.00 (36.4–75.0) 47.9 (24.1–78.16) 0.398b
Parameters Before stimulation After stimulation P
GnRH antagonists
SOD, U/L 17.56 (15.57–19.61) 14.5 (12.97–16.03) <0.001
MDA, mmol/L 1.40 (1.29–1.50) 1.71 (1.49–1.93) <0.001
SH groups, mmol/L 0.24 (0.19–0.29) 0.47 (0.34–0.57) <0.001
GnRH agonists
SOD, U/L 17.37 (16.58–19.99) 14.08 (12.59–15.22) <0.001 
MDA, mmol/L 1.38 (1.26–1.46) 1.78 (1.45–1.96) 0.003  
SH groups, mmol/L 0.24 (0.17– 0.32) 0.51 (0.42–0.57) <0.001 
Parameters GnRH antagonists GnRH agonists P
SOD, U/L 14.5 (12.97–16.03) 14.08 (12.59–15.22) 0.289
MDA, mmol/L 1.71 (1.49–1.93) 1.78 (1.45–1.96) 0.561  
SH groups, mmol/L 0.47 (0.34–0.57) 0.51 (0.42–0.57) 0.207
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The embryo quality was evaluated in women
with different stimulation protocols. Independently of
the stimulation protocol, embryos class A prevailed in
women with 44% of women stimulated by short pro-
tocols and 57% of women stimulated by long proto-
cols. The quality of the embryo in relation to this cri-
terion was not significantly different between the
groups (p=0.684; c2 test).
Concerning the outcome of IVF, there were no
significant differences in live–birth rate in both groups
(p=0.828; c2 test). Miscarriage rate (p=0.894) as
well as the rate of biochemical pregnancies
(p=0.449) were similar in both groups. The effect of
different protocols of ovarian stimulation on oxidative
stress parameters in serum was shown in Table II. In
40 women with short GnRH antagonist protocols
SOD activity was significantly lower while MDA and
SH-groups levels were higher after ovarian stimula-
tion. In long agonist protocols the results were similar.
In GnRHant group, mean serum SOD was significant-
ly lower (17.56 vs. 14.5 U/L, p<0.001), while mean
serum MDA value (1.40 vs. 1.71 micromole/L,
p<0.001) and SH-groups content were significantly
higher (0.24 vs. 0.47 mmol/L, p<0.001) after ovari-
an stimulation (Table II). In GnRHa group the results
were similar, the mean serum SOD was significantly
lower (17.37 vs. 14.08 U/L, p<0.001), while mean
serum MDA (1.38 vs. 1.78 mmol/L, p=0.003) and
SH groups (0.24 vs. 0.51 mmol/L, p<0.001) were
significantly higher after ovarian stimulation (Table II).
We compared differences in oxidative stress parame-
ters after ovarian stimulation between GnRHant and
GnRHa groups. There were no significant differences
in concentrations of SOD (14.5 vs. 14.08 U/L, p=
0.289), MDA (1.71 vs. 1.78 mmol/L, p=0.561) and
SH groups (0.47 vs. 0.51 mmol/L, p=0.207) bet -
ween the two groups after ovarian stimulation (Table
III). 
As there was a difference in the oxidative stress
parameters after ovarian stimulation, we examined its
influence on the IVF outcome. All patients with SOD
activity less than the 25th percentile after and MDA
and SH concentrations higher than the 75th per-
centile after ovarian stimulation were in the group
with OS after ovarian stimulation (62.7%). Other
patients were in the group without induced OS after
ovarian stimulation (p<0.021; c2 test). There was no
difference in the number and quality of oocytes,
embryo quality, fertilization and pregnancy rate
between patients with and without OS after ovarian
stimulation. However, patients without oxidative stress
after ovarian stimulation had a delivery rate of 82% and
no miscarriage, while patients with OS had a delivery
rate of 68% (p=0.347) and a miscarriage rate of
31.8% (p=0.040) (Table IV).
Discussion
The success of ART procedures depends on
several factors, including the protocol of controlled
ovarian stimulation applied. Which protocol will be
applied depends on several factors, among which are:
age, basal hormonal status, number of antral follicles,
previous IVF and others. 
Stimulation protocols with GnRH antagonists
have a number of advantages in comparison to
protocols with GnRH agonists, such as the
significantly shorter duration of treatment and the
lower total dose of gonadotropin used in stimulation
(17, 18). Another advantage is a lower risk of
developing the ovarian hyperstimulation syndrome
(19). How ever, the impact on the outcome of IVF and
preg nancy rates is controversial (20, 21). Therefore,
we in ves tigated the impact of different stimulation
protocols on the outcome of IVF. In our study, sti -
mulation protocols were determined individually. The
results showed that the fertilization rate, quality of
embryos as well as pregnancy and live–birth rates
were similar in GnRH antagonist and GnRH agonist
protocols. This finding is consistent with the meta-
analysis that in cluded five ran domized trials
comparing the GnRHa and GnRGant GnRH pro to -
cols and showed similar rates of implantation and
pregnancies per cycle in both protocols (22). Other
studies had similar results (19, 20). It was also shown
that there was no detrimental effect on the em bryos
when large doses of GnRH anta go nists were
administrated and no differences in de li very rates in
GnRH agonist as compared to GnRH anta gonist
cycles (21). However, the number of mature oocy tes
as well as the number of fertilized oocytes were higher
in the GnRHa group, which could be explained by the
higher number of obtained oocytes and younger age. 
Values of basal FSH (24) and E2 (23) are widely
used as a prognostic test for ovarian reserve. The first
study to link the value of FSH and E2 with the out -
come of assisted reproduction suggested that the
measurement of basal values of estradiol and FSH
may provide a more accurate prediction of the repro-
ductive potential than individual FSH levels combined
with age (25). Also, it has been demonstrated that
elevated estradiol values in the early follicular phase
have a worse prognosis, with a higher rate of cycle
cancelation and lower pregnancy rate after IVF, regar-
dless of FSH levels (26).
Table IV Pregnancy outcome in patients with and without
OS after ovarian stimulation.
Pregnancy 
outcome Without OS With OS P
Delivery rate % 81.8 68.2 0.347
Miscarriage rate % 0 31.8 0.040
Biochemical 
pregnancy % 18.2 0 0.104
The development of immunoassays for protein
hormones such as AMH has led to its growing use in
the prediction of ovarian reserve (27). AMH is a di -
meric glycoprotein produced by the granulosa cells of
preantral and small antral follicles. The size of small
antral follicle pool is related to the size of the pool of
primordial follicles which is the true measure of ovar-
ian reserve. The small antral follicle pool number
decreases with age; AMH production diminishes and
it is undetectable in menopause. Unlike other bio-
chemical markers, it can be measured at any day of
the cycle (28). It is a marker of ovarian reserve and
the predictor of quantitative reaction to exogenous
ovarian stimulation in ART procedures. The various
thresholds of 0.2–1.26 ng/mL are markers of poor
ovarian response with 80–87% sensitivity and
64–93% specificity. However, values > 5.0 ng/mL are
related to the polycystic ovary syndrome (PCOS).
Serum levels of AMH are not good predictors for
pregnancy (29, 30). In assisted reproductive cycles,
women with a poor response had lower values of
AMH and a smaller number of antral follicles before
the start of ovarian stimulation than women with a
good response to exogenous gonadotropins (31).
A higher level of FSH in the follicular phase is
associated with poor ovarian response (32), while a
higher value of AMH is associated with good ovarian
response (33). Concerning the basal hormonal sta-
tus, statistically significant differences in the values of
FSH (p=0.044) and AMH (p<0.007) were observed,
which contribute to the number of obtained oocytes.
AMH values were significantly lower in the GnRHant
group, while FSH values were significantly higher.
These data suggest a decreased ovarian reserve as
the possible common cause of infertility in this group,
and it has been shown that in 32.2% of cases it was
a disorder of ovarian function, which in our work was
the most common cause of infertility in this group.
However, higher values of AMH in the GnRH agonist
group can be explained by the younger patients
submitted to long protocols. Still, a lower number of
mature ooytes in the GnRH antagonist group needs
further assessment. 
In combination with genetic predisposition and
lifestyle habits, the outcome of IVF can be signi fi -
cantly altered by stress and natural defense mecha -
nisms necessary to overcome it (34). Different studies
investigated the correlation between administration of
gonadotropins and IVF outcome (35). Controlled
ova rian stimulation can lead to disruption of oxida-
tive-antioxidative balance. In our study, we showed
that ovarian stimulation in IVF induces oxidative
stress, which can be detected in serum. We also
showed that patients without OS after ovarian stimu-
lation had a better IVF outcome. When we compared
the effects of different stimulation protocols on the
parameters of oxidative status, SOD activity was
decreased after stimulation, while the content of
MDA and SH groups were increased after stimula-
tion. However, the value of SOD, MDA and SH
groups did not differ significantly among patients with
different stimulation protocols. Similar results were
reported by Aurrekoerxea et al. (3). Other studies
have also shown that ovarian stimulation has an
impact on the activity of SOD, GPx and IL-6 level
(36). Oral et al. (37) found that the levels of MDA
were lower in the group that was pregnant, suggest-
ing that the MDA level could be used as a predictive
marker of the success of IVF. Pallini et al. (38) found
no difference in the values of antioxidants con -
centration  after suppression of the pituitary gland
when comparing with the values before treatment.
However, it has been shown that sti mu lation leads to
a decrease in antioxidant concen trations in plasma
and reduction of protection against oxidation in the
serum, when the con cen tration of anti oxidants in
serum after gonado tropin sti mulation is compared in
women undergoing IVF with that in women in the
follicular phase of the natural cycle (3). The reduction
of antioxidants after ovarian sti mula tion is consistent
with the results obtained in our study and may be due
to the administration of GT. 
In summary, ovarian stimulation causes a differ-
ence in SOD activity, MDA and SH groups concentra-
tions in serum in both GnRHa and GnRHant proto-
cols, but the change in oxidative stress parameters is
similar in both protocols. Protocol of stimulation does
not affect IVF outcome; namely, the quality of oocytes
and embryos, fertilization, pregnancy and miscarriage
rates are similar in both protocols. However, the
change in oxidative stress parameters affects IVF out-
come; patients with induced oxidative stress after
ovarian stimulation had a lower delivery rate and a
higher miscarriage rate compared to patients with
normal oxidative status. 
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